---
layout: post
title: "Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer"
date: 2026-02-06T09:00:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/kelun-biotech-announces-fourth-indication-for-sacituzumab-tirumotecan-sac-tmt-approved-by-nmpa-in-hrher2--breast-cancer-302681155.html
significance: 7.20
---

<p>CHENGDU, China, Feb. 6, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its TROP2-directed ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) has been...</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/kelun-biotech-announces-fourth-indication-for-sacituzumab-tirumotecan-sac-tmt-approved-by-nmpa-in-hrher2--breast-cancer-302681155.html)

**Published:** 2026-02-06 09:00:00 +0000

**Significance Score:** 7.20

[View original](https://www.prnewswire.com/news-releases/kelun-biotech-announces-fourth-indication-for-sacituzumab-tirumotecan-sac-tmt-approved-by-nmpa-in-hrher2--breast-cancer-302681155.html)
